Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25969224 | 0.83 | ALDH1A1 (0.39) | ALDH1A1HTTRAB9ABCL2A1CNR2 | |
| SCHEMBL25969225 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HTTRAB9APYCR1SMN1; SMN2 | |
| SCHEMBL23641242 | 0.69 | ALDH1A1 (0.56) | ALDH1A1HTTRAB9APYCR1SMN1; SMN2 | |
| SCHEMBL23789094 | 0.68 | ALDH1A1 (0.54) | ALDH1A1HTTRAB9APYCR1SMN1; SMN2 | |
| SCHEMBL6412640 | 0.67 | ALDH1A1 (0.68) | ALDH1A1HTTRAB9APYCR1SMN1; SMN2 | |
| SCHEMBL13769106 | 0.67 | ALDH1A1 (0.58) | ALDH1A1HTTRAB9APYCR1SMN1; SMN2 | |
| SCHEMBL17887509 | 0.66 | ALDH1A1 (0.61) | ALDH1A1HTTRAB9APYCR1SMN1; SMN2 | |
| SCHEMBL11300231 | 0.66 | ALDH1A1 (0.66) | ALDH1A1HTTRAB9APYCR1SMN1; SMN2 | |
| SCHEMBL4573297 | 0.66 | PYCR1 (0.52) | ALDH1A1HTTRAB9APYCR1SMN1; SMN2 | |
| SCHEMBL197287 | 0.65 | HRH3 (0.64) | ALDH1A1HTTRAB9APYCR1LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SHH, GLI1, SMO | ALDH1A1 786/4885HTT 2727/4885RAB9A 920/4885 |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SHH, GLI1, SMO | ALDH1A1 786/4885HTT 2727/4885RAB9A 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.